TABLE 2

Receptor affinity assessed with either [3H]Org 43553 or 125I-hCG, and receptor activity of compounds 1-6 and recombinant LH at the human luteinizing hormone receptor.

Embedded ImageEmbedded Image

1-5


6

Compound
R1
R2
R3
[3H]Org 43553 Bindinga
[125I]hCG Bindingb
EC50c
nM
1 (Org 41841) SMe OMe tBu 17 ± 5 1 (0-1) 13 ± 1
2 (Org 41247) Ph OMe iPr 100 ± 6 4 (0-8) 119 ± 18
3 (Org 42619) SMe Embedded Image tBu 4.7 ± 0.7 0 (0-0) 3.0 ± 0.5
4 (Org 43311) SMe Embedded Image tBu 4.1 ± 0.7 4 (0-7) 1.3 ± 0.4
5 (Org 43553) SMe Embedded Image tBu 3.3 ± 0.3 7 (6-8) 1.7 ± 0.2
6 (Org 43983) 82 ± 17 0 (0-0) 111 ± 3
recLH



32 (31-33)d
0.61 ± 0.1e
0.078 ± 0.002
  • * Position of the tritium substitution in Org 43553.

  • a Displacement of specific [3H]Org 43553 binding from human luteinizing hormone receptors stably expressed on CHO-K1 cell membranes [Ki ± S.E.M. (nM), n ≥ 3, duplicate].

  • b Percentage displacement of specific 125I-hCG binding from human luteinizing hormone receptors stably expressed on CHO-K1 cell membranes at 10 μM concentrations (n = 2, duplicate).

  • c cAMP-mediated luciferase activity in CHO-K1 cells that stably express the human luteinizing hormone receptor and CRE-luciferase reporter gene (mean ± S.E.M., n ≥ 3, duplicate).

  • d Percentage displacement of specific [3H]Org 43553 binding at 70 nM recLH (n = 4, duplicate).

  • e Displacement of specific 125I-hCG binding [Ki ± S.E.M. (nM), n = 3, duplicate].